Published in JAMA on May 05, 2010
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med (2012) 2.03
Vitamin C supplementation for pregnant smoking women and pulmonary function in their newborn infants: a randomized clinical trial. JAMA (2014) 1.68
Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med (2011) 1.49
Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol (2011) 1.43
Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA (2012) 1.25
Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax (2012) 1.12
Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest (2012) 0.95
Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial. Contemp Clin Trials (2013) 0.94
Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Front Microbiol (2014) 0.90
Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis. J Antimicrob Chemother (2013) 0.88
The sensitivity of lung disease surrogates in detecting chest CT abnormalities in children with cystic fibrosis. Pediatr Pulmonol (2011) 0.88
New and emerging targeted therapies for cystic fibrosis. BMJ (2016) 0.87
Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc (2014) 0.85
Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother (2013) 0.82
Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge. Br J Pharmacol (2014) 0.82
Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Expert Rev Precis Med Drug Dev (2016) 0.82
Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis. Pediatr Pulmonol (2014) 0.81
Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. Antimicrob Agents Chemother (2013) 0.81
Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis. Pediatr Res (2012) 0.81
Prevention of antibiotic-associated metabolic syndrome in mice by intestinal alkaline phosphatase. Diabetes Obes Metab (2016) 0.80
Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis. Clin Infect Dis (2015) 0.80
Evidence and Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease. PLoS Pathog (2016) 0.80
Impact of Azithromycin on the Quorum Sensing-Controlled Proteome of Pseudomonas aeruginosa. PLoS One (2016) 0.79
Azithromycin use in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis (2015) 0.78
Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis. ScientificWorldJournal (2013) 0.78
Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. J Clin Microbiol (2011) 0.78
Potential of anti-inflammatory treatment for cystic fibrosis lung disease. J Inflamm Res (2010) 0.78
Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. J Cyst Fibros (2013) 0.78
The Evolution of Cystic Fibrosis Care. Chest (2015) 0.78
Cystic Fibrosis: Microbiology and Host Response. Pediatr Clin North Am (2016) 0.78
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med (2016) 0.77
The role of macrolides in childhood non-cystic fibrosis-related bronchiectasis. Mediators Inflamm (2012) 0.77
Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. J Cyst Fibros (2014) 0.77
Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. J Bras Pneumol (2013) 0.76
Azithromycin paradox in the treatment of cystic fibrosis airway disease. Future Microbiol (2010) 0.76
Outcomes and Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Differs by Staphylococcal Cassette Chromosome mec (SCCmec) Type in Children With Cystic Fibrosis. J Pediatric Infect Dis Soc (2014) 0.76
Biomarkers for cystic fibrosis drug development. J Cyst Fibros (2016) 0.75
Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher. J Cyst Fibros (2017) 0.75
Macrolides for Acute Wheezing Episodes in Preschool Children. Pediatr Allergy Immunol Pulmonol (2016) 0.75
Azithromycin for the treatment of eosinophilic nasal polyposis: Clinical and histologic analysis. Allergy Rhinol (Providence) (2016) 0.75
Azithromycin Attenuates Pseudomonas-Induced Lung Inflammation by Targeting Bacterial Proteins Secreted in the Cultured Medium. Front Immunol (2016) 0.75
The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis. Front Pediatr (2017) 0.75
Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. J Cyst Fibros (2015) 0.75
Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia. BMC Pulm Med (2016) 0.75
Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. Contemp Clin Trials (2012) 0.75
Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ (2017) 0.75
MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology. Nat Commun (2017) 0.75
Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med (2003) 9.78
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A (2006) 8.85
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Hospital volume and the outcomes of mechanical ventilation. N Engl J Med (2006) 5.67
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med (2007) 4.34
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA (2003) 4.31
Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J (2013) 3.34
Clinician statements and family satisfaction with family conferences in the intensive care unit. Crit Care Med (2006) 3.08
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol (2007) 2.87
The burden of influenza-associated critical illness hospitalizations. Crit Care Med (2014) 2.84
Cystic fibrosis adult care: consensus conference report. Chest (2004) 2.70
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med (2009) 2.65
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med (2014) 2.63
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax (2007) 2.60
Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care (2010) 2.52
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med (2002) 2.50
Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa. J Bacteriol (2003) 2.41
Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med (2010) 2.40
Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest (2010) 2.29
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med (2003) 2.26
The relationship between single-breath diffusion capacity of the lung for nitric oxide and carbon monoxide during various exercise intensities. Chest (2004) 2.23
Monitoring influenza activity in the United States: a comparison of traditional surveillance systems with Google Flu Trends. PLoS One (2011) 2.21
Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax (2013) 2.20
Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr (2009) 2.16
Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med (2014) 2.15
A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol (2011) 2.14
Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med (2005) 2.13
Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol (2010) 2.11
Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol (2012) 2.08
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med (2011) 2.04
Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.03
Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax (2010) 1.97
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr (2008) 1.96
Statement on Exercise Testing in Cystic Fibrosis. Respiration (2015) 1.93
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (2004) 1.91
Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. J Clin Microbiol (2002) 1.87
Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med (2002) 1.87
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest (2003) 1.86
Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med (2010) 1.82
Diagnostic value of nasal nitric oxide measured with non-velum closure techniques for children with primary ciliary dyskinesia. J Pediatr (2011) 1.81
Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest (2006) 1.79
Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med (2013) 1.76
Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat Biotechnol (2012) 1.73
Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics (2008) 1.72
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros (2008) 1.71
Skeletal muscle metabolism in cystic fibrosis and primary ciliary dyskinesia. Pediatr Res (2011) 1.70
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.70
Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis. Environ Microbiol (2003) 1.68
A story of success: continuous quality improvement in cystic fibrosis care in the USA. Thorax (2011) 1.68
Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr (2010) 1.67
Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med (2014) 1.66
Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros (2011) 1.65
Development of a predictive model for long-term survival after lung transplantation and implications for the lung allocation score. J Heart Lung Transplant (2010) 1.64
Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status. Am J Respir Crit Care Med (2012) 1.64
Risk of post-lung transplant renal dysfunction in adults with cystic fibrosis. Chest (2012) 1.60
Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med (2012) 1.59
Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One (2011) 1.58
Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care (2010) 1.57
The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest (2009) 1.56
beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics (2002) 1.54
Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia. Respiration (2009) 1.54
Risk factors for chronic kidney disease in adults with cystic fibrosis. Am J Respir Crit Care Med (2011) 1.53
Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. Eur Respir J (2013) 1.53
Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol (2010) 1.53
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemp Clin Trials (2009) 1.53
Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway. PLoS Pathog (2010) 1.50
Alveolar macrophage secretory products augment the response of rat pulmonary artery endothelial cells to hypoxia and reoxygenation. Ann Thorac Surg (2008) 1.47
Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. Respiration (2009) 1.46
Comparative effectiveness research: what happened to incorporating costs of care? Am J Respir Crit Care Med (2011) 1.45
Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr (2007) 1.45
Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. J Clin Microbiol (2003) 1.40
Factors associated with mortality in patients with tuberculosis. BMC Infect Dis (2010) 1.39
Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest (2007) 1.38
A preliminary evaluation of the effectiveness of the Cystic Fibrosis Foundation Mentoring Program for Respiratory Care. Respir Care (2013) 1.38
Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med (2008) 1.37
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol (2006) 1.34
Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin Infect Dis (2013) 1.34